Advances in cytology of lung cancer |
| |
| Institution: | 1. Department of Pathology, All India Institute of Medical Sciences, New Delhi, India;2. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;1. Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, TN, United States;2. Department of Pathology, New York University (NYU) Long Island, Winthrop Hospital, Mineola, NY, United States;3. Department of Pathology and Laboratory Medicine, Children''s Hospital Los Angeles, Los Angeles, CA, United States;1. Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia;2. Sydney Medical School, University of Sydney, Sydney, NSW, Australia;3. School of Medicine, Western Sydney University, Sydney, NSW, Australia;4. Department of Anatomical Pathology, Singapore General Hospital, Singapore;1. Department of Oncology, University of Turin, Turin, Italy;2. Cancer Biomarker Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy;3. Operative Unit of Pathologic Anatomy, Azienda USL Romagna, Hospital Santa Maria delle Croci, Ravenna, Italy;4. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy;5. Department of Pathology and Laboratory Medicine, IRCCS Istituto Nazionale dei Tumori, Milan, Italy;6. Department of Medical Sciences and Community Health, University of Milan, Milan, Italy;7. Division of Pneumology, San Giuseppe Hospital, IRCCS MultiMedica, Milan, Italy;8. Inter-Hospital Pathology Division, IRCCS MultiMedica, Milan, Italy |
| |
| Abstract: | Cytopathology has emerged as a promising platform in precision oncology especially after the revolutionary change in our understanding of the concept of lung cancer etiopathogenesis. With increasing use of minimally invasive techniques for sample acquisition, it becomes almost mandatory to utilize precious cytology samples maximally and judiciously by appropriate triaging of the specimen and timely action of the cytopathology team. Existing patient management protocols require accurate morphologic and molecular diagnosis of the lung cancer specimens which needs knowledge about evolving techniques related to specimen procurement, updates of genomic variants of lung cancer and recently developed molecular testing platforms and algorithms which are capable enough to use even miniscule amount of diagnostic material. This review provides a brief knowledge about advances in cytology of lung cancer which are helpful for developing correct clinical management strategies. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
